Trial Profile
A Phase II trial of Preoperative chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 14 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Mar 2018 Planned primary completion date changed from 1 May 2017 to 1 May 2022.